Tempus AI and Gilead Sciences have announced an expanded, multi‑year partnership designed to accelerate the development of Gilead’s oncology pipeline. The deal builds on the companies’ existing relationship, extending data sharing and joint development of new therapies through Tempus’ de‑identified multimodal data and AI‑enabled Lens platform.
The agreement does not disclose a financial value, but it grants Gilead enterprise‑wide access to Tempus’ AI‑driven analytics and a dedicated team of data scientists. The expansion deepens the exchange of genomic, clinical, and imaging data, enabling more precise trial design, biomarker discovery, and real‑world evidence generation for Gilead’s oncology programs.
For Tempus, the partnership reinforces its position as a key data partner for major pharmaceutical companies and could open new revenue opportunities as the collaboration progresses. For Gilead, the expansion aligns with its broader strategy to diversify its oncology portfolio following recent acquisitions of Arcellx, Ouro Medicines, and Tubulis. Patrick Loerch, SVP of Clinical Data Science at Gilead, said the partnership "reflects our shared priority of putting patients at the heart of innovation," while Ryan Fukushima, CEO of Tempus Data & Apps, noted that the expanded collaboration "empowers the Gilead team to further fuel its R&D engine with AI‑driven insights."
The collaboration exemplifies the growing trend of pharmaceutical companies integrating real‑world data and AI to accelerate drug discovery, optimize clinical trial design, and identify predictive biomarkers. By combining Gilead’s scientific expertise with Tempus’ extensive multimodal dataset, the partnership aims to accelerate the development of new oncology therapies across multiple indications.
The expanded collaboration signals a significant deepening of the partnership and could create new revenue opportunities for Tempus while accelerating Gilead’s oncology development, underscoring the strategic importance of data‑driven innovation in the pharmaceutical industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.